Last reviewed · How we verify
NCT04592835
To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003
Phase 1 trial testing DWRX2003 in COVID-19 Patients in 24 participants. Status unknown.
13 December 2020
Quick facts
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 19 October 2020 |
| Primary completion | 13 December 2020 |
| Estimated completion | 30 June 2021 |
Drugs / interventions tested
- DWRX2003 — full drug profile →
Conditions studied
- COVID-19 Patients — all drugs for COVID-19 Patients →
Sponsor
Daewoong Pharmaceutical Co. LTD. — full company profile →
Who can join
Adults 18 to 65, any sex, with COVID-19 Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed to assess the safety, tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) in healthy volunteers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Niclosamide-A promising treatment for COVID-19.
Singh S, Weiss A, Goodman J, Fisk M, et al · · 2022 · cited 64× · PMID 35348204 · DOI 10.1111/bph.15843
Verify or expand the search:
- PubMed search for NCT04592835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of DWRX2003
Trials testing the same drug.
- NCT05226533 — Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Pat · Phase 2 · terminated
- NCT04541485 — To Evaluate Safety, Tolerability and Pharmacodynamics of DWRX2003 Against COVID-19 (in Philippines) · Phase 1 · terminated
Other recruiting trials for COVID-19 Patients
Currently open trials in the same condition.
- NCT06349720 — Investigating Long-term Health Effects and Complications in COVID-19 Recoveries · recruiting
Other Daewoong Pharmaceutical Co. LTD. trials
Trials by the same sponsor.
- NCT07515560 — Efficacy and Safety of Baroezet Tablet in Korean Patients With Dyslipidemia: A Prospective Observational Study · not yet recruiting
- NCT07516977 — Noseguard for Prevention of Respiratory Infections in Real-World Use · NA · not yet recruiting
- NCT07539415 — A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Hea · Phase 1 · not yet recruiting
- NCT07267221 — Bioequivalence Study for the Safety and the Pharmacokinetics of DWC202313, DWC202314, and DWJ1622 in Healthy Volunteers · Phase 1 · recruiting
- NCT07256600 — PK and Safety Comparison of DWJ445 and DWC202506 in Healthy Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04592835 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Daewoong Pharmaceutical Co. LTD.
- Last refreshed: 19 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04592835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing